Table 2.
Blood pressure and body weight changes compared to placebo after at least 1-year of treatment with anti-obesity medications approved for long-term treatment of obesity. [[11], [12], [13], [14],141,145,146] The listed blood pressures are not from head-to-head controlled clnical trials and only intended to provide a general overview of potentially expected blood pressure responses. Some of the reported values are pooled data, and may not be consistent with individual studies – especially those studies less than one year. The reported blood pressure reduction with bariatric surgery is heterogenous, depending on the study, procedure, and duration of follow-up with study suggesting an average of 9 mmHg reduction in systolic blood pressure, variable effects on diastolic blood pressure [147], and greater weight reduction associated with higher rates of hypertension remission [148].
| Anti-Obesity Medication | Systolic blood pressure (mmHg) | Diastolic blood pressure (mmHg) | % Weight reduction |
|---|---|---|---|
| Phentermine/topiramate | -3 | -1 | -9 |
| Naltrexone/bupropion | +1.5 | +1 | -4 |
| Orlistat | -1 | -1 | -3 |
| Liraglutide | -3 | -1 | -5 |
| Semaglutide | -5 | -2.4 | -12 |
| Tirzepatidea | -6 | -4 | -18% |
Tirzepatide is not approved for treatment of obesity at the time of this writing. Shown are the blood pressure effects of the tirzepatide 15 mg dose when studied in patients with obesity and without diabetes mellitus.